A Comprehensive Review on Cardiovascular Diseases: Epidemiology, Pathophysiology, and Emerging Therapeutic Strategies

Senthilkumar V., *Barath Nithish K., Aravindh S., Chan Begam A., Mouli S., Rajalingam D., Gnanasekar N.

Department of Pharmacy Practice, Kamalakshi Pandurangan College of Pharmacy, Tiruvannamalai. 606 603. Tamil Nadu, India. (Affiliated to The TN Dr. M.G.R Medical University, Chennai-32).

***Corresponding Author**

DOI: https://doi.org/10.51244/IJRSI.2026.1304000006

Received: 02 April 2026; Accepted: 07 April 2026; Published: 23 April 2026

ABSTRACT

Cardiovascular diseases (CVDs) constitute the leading cause of mortality and morbidity globally, representing a major public health challenge in both developed and developing nations. The increasing prevalence of CVD is strongly associated with rapid urbanization, sedentary lifestyle, unhealthy dietary habits, and an aging population. This review provides a comprehensive and updated overview of cardiovascular diseases, focusing on epidemiology, pathophysiological mechanisms, risk factors, current treatment modalities, emerging therapeutic strategies, and recent clinical trial evidence. The pathogenesis of CVD is multifactorial, involving endothelial dysfunction, lipid accumulation, chronic inflammation, and thrombogenesis, ultimately leading to atherosclerosis and its complications. Conventional pharmacological interventions, including antihypertensive agents, lipid-lowering drugs, antiplatelet agents, and anticoagulants, remain the cornerstone of management. However, novel therapeutic approaches such as PCSK9 inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and gene-based therapies have demonstrated significant clinical benefits in recent studies. Additionally, advancements in artificial intelligence and precision medicine are revolutionizing early diagnosis and individualized treatment strategies. This review aims to highlight recent developments and provide insights into future directions for effective prevention and management of cardiovascular diseases.

Keywords- cardiovascular disease; Atherosclerosis; Hypertension; Dyslipidemia; Pharmacotherapy; PCSK9 inhibitors; SGLT2 inhibitors; Clinical trials; Precision medicine; Endothelial dysfunction

INTRODUCTION

Cardiovascular diseases (CVDs) encompass a broad spectrum of disorders affecting the heart and vascular system, including coronary artery disease (CAD), cerebrovascular disease (stroke), heart failure, peripheral arterial disease, and hypertension [1]. These conditions collectively impose a significant burden on healthcare systems worldwide [2]. Over the past few decades, the epidemiological transition from communicable to non-communicable diseases has resulted in a marked increase in CVD prevalence, particularly in low- and middle-income countries such as India [3].

The pathophysiology of CVD is complex and multifactorial, involving interactions between genetic predisposition, environmental exposures, and behavioral risk factors [4]. Despite advancements in pharmacological and interventional therapies, the incidence of cardiovascular events remains high, highlighting the need for improved preventive and therapeutic strategies [5]. This review aims to provide a detailed and structured overview of cardiovascular diseases with a focus on recent advancements relevant to clinical and pharmaceutical research.

ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XIII Issue IV April 2026

Epidemiology of Cardiovascular Diseases

Cardiovascular diseases account for approximately 17.9 million deaths annually, representing nearly 32% of all global deaths [2]. Among these, coronary artery disease and stroke are the leading contributors [6]. A significant proportion of CVD-related deaths occur prematurely, particularly in individuals below the age of 70 years [2].

In India, the burden of CVD has increased dramatically due to rapid urbanization, lifestyle changes, and increased life expectancy [7]. Studies indicate that the prevalence of ischemic heart disease has nearly doubled in the past two decades [8]. Urban populations exhibit a higher prevalence compared to rural areas, although rural incidence is also rising [7]. Additionally, there is a concerning trend of earlier onset of CVD among younger individuals, attributed to increased prevalence of risk factors such as diabetes, hypertension, and obesity [9].

Socioeconomic factors, limited access to healthcare, and lack of awareness further exacerbate the burden of CVD in developing countries [7].

Pathophysiology of Cardiovascular Diseases

The fundamental mechanism underlying most cardiovascular diseases is atherosclerosis, a chronic inflammatory condition characterized by the accumulation of lipids, inflammatory cells, and fibrous elements within arterial walls [10].

The process begins with endothelial dysfunction, triggered by factors such as hypertension, smoking, and hyperglycemia [11]. This leads to increased permeability of the endothelium and accumulation of low-density lipoprotein (LDL) cholesterol in the intima [10]. Oxidized LDL stimulates an inflammatory response, attracting monocytes that differentiate into macrophages and form foam cells [12]. These foam cells contribute to the formation of fatty streaks, which progressively develop into fibrous plaques [10].

Plaque instability and rupture can result in thrombus formation, leading to acute cardiovascular events such as myocardial infarction or stroke [13]. Additional mechanisms involved include oxidative stress, neurohormonal activation, and vascular remodeling, particularly in conditions like heart failure [14].

Risk Factors of Cardiovascular Diseases [15,16,17,18,19,20]

Modifiable Risk Factors

Modifiable risk factors play a crucial role in the development and progression of CVD and are the primary targets for preventive strategies.

- Hypertension: Major contributor to stroke and heart disease.
- Dyslipidemia: Elevated LDL and reduced HDL levels
- Diabetes Mellitus: Accelerates atherosclerosis
- Smoking: Causes endothelial damage and thrombosis
- Obesity: Associated with metabolic syndrome
- Physical Inactivity: Increases cardiovascular risk.
- Unhealthy Diet: High salt, sugar, and saturated fat intake

Non-Modifiable Risk Factors

- Age: Risk increases with advancing age

ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XIII Issue IV April 2026

- Gender: Higher risk in males (pre-menopause)
- Genetics: Family history of CVD
- Ethnicity: Certain populations have higher susceptibility.

Current Treatment Strategies

- **Pharmacological Management**

1. **Anti-hypertensive Agents:**

ACE inhibitors, angiotensin receptor blockers (ARBs), beta-blockers, calcium channel blockers, and diuretics are widely used to control blood pressure and reduce cardiovascular risk [22].

Lipid-Lowering Agents:

Statins remain the first-line therapy for dyslipidemia due to their proven efficacy in reducing LDL cholesterol and cardiovascular events [23].

Antiplatelet Agents:

Aspirin and P2Y12 inhibitors (clopidogrel, ticagrelor) are essential in preventing thrombotic events [24].

Anticoagulants:

Warfarin and direct oral anticoagulants (DOACs) are used in conditions such as atrial fibrillation and venous thromboembolism [25].

Heart Failure Management:

Includes diuretics, beta-blockers, ACE inhibitors, ARNI, and mineralocorticoid receptor antagonists [26].

Non-Pharmacological Management

- Lifestyle modification (diet, exercise).
- Smoking cessation
- Weight management
- Stress reduction

Emerging Therapeutic Approaches

- Recent advances in cardiovascular research have led to the development of innovative, targeted therapeutic strategies that extend beyond conventional treatments and significantly improve clinical outcomes. Among these, **proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors** have emerged as a breakthrough in lipid management. Agents such as evolocumab and alirocumab act by inhibiting PCSK9-mediated degradation of low-density lipoprotein (LDL) receptors, thereby enhancing hepatic clearance of LDL cholesterol. Clinical trials have demonstrated profound reductions in LDL-C levels and a corresponding decrease in major adverse cardiovascular events, making these agents particularly valuable in high-risk patients and those intolerant to statins [28].
- Another major advancement is the introduction of **sodium-glucose co-transporter 2 (SGLT2) inhibitors**, initially developed for the management of type 2 diabetes mellitus. Drugs such as empagliflozin and dapagliflozin have shown significant cardiovascular benefits, including reductions in hospitalization for

heart failure and cardiovascular mortality. These effects are attributed not only to glycemic control but also to mechanisms such as osmotic diuresis, reduction in preload and afterload, improved myocardial energy utilization, and attenuation of cardiac remodeling [29].

- Similarly, **glucagon-like peptide-1 (GLP-1) receptor agonists** have demonstrated cardioprotective effects in patients with diabetes and high cardiovascular risk. Agents such as liraglutide and semaglutide improve glycemic control, promote weight loss, and reduce blood pressure, while also exerting direct anti-atherosclerotic and anti-inflammatory effects. Clinical studies have reported a reduction in major cardiovascular events, further supporting their role in comprehensive cardiovascular risk management [30].

- In addition to pharmacological agents, **gene therapy** represents a promising frontier in cardiovascular medicine. This approach aims to correct or modulate genetic abnormalities associated with lipid metabolism and atherosclerosis by delivering functional genes or silencing defective ones. Techniques such as viral vector-mediated gene transfer and genome editing hold potential for long-term therapeutic benefits, particularly in inherited lipid disorders [31].

- Furthermore, **stem cell therapy** is being explored for its regenerative potential in cardiovascular diseases, especially in myocardial infarction and heart failure. Stem cells, including mesenchymal stem cells and induced pluripotent stem cells, have the ability to differentiate into cardiomyocytes and vascular cells, thereby promoting myocardial repair, angiogenesis, and functional recovery of damaged cardiac tissue [32].

- Another cutting-edge development is the use of **RNA-based therapies**, particularly small interfering RNA (siRNA) molecules, which target specific genes involved in lipid metabolism. For instance, inclisiran inhibits the synthesis of PCSK9 at the genetic level, resulting in sustained LDL-C reduction with infrequent dosing. These therapies offer a novel mechanism of action with the potential for long-lasting effects and improved patient adherence [33].

Recent Clinical Trials

Recent large-scale randomized clinical trials have significantly advanced the understanding and management of cardiovascular diseases by demonstrating the efficacy of targeted therapeutic approaches. The FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) evaluated the monoclonal antibody evolocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in patients with established atherosclerotic cardiovascular disease receiving statin therapy. The study demonstrated a substantial reduction in low-density lipoprotein cholesterol (LDL-C) levels, along with a significant decrease in major adverse cardiovascular events (MACE), including myocardial infarction, stroke, and coronary revascularization [28].

Similarly, the ODYSSEY OUTCOMES trial investigated the effects of alirocumab, another PCSK9 inhibitor, in patients who had experienced a recent acute coronary syndrome (ACS). The trial reported a marked reduction in recurrent ischemic cardiovascular events and all-cause mortality, particularly in patients with higher baseline LDL-C levels, thereby reinforcing the role of intensive lipid-lowering strategies in secondary prevention [34].

In addition to lipid-lowering therapies, glucose-lowering agents have shown remarkable cardiovascular benefits. The EMPA-REG OUTCOME trial assessed the sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease. The results revealed a significant reduction in cardiovascular mortality, hospitalization for heart failure, and all-cause mortality, suggesting mechanisms beyond glycemic control, such as improved hemodynamics and reduced cardiac workload [29].

Furthermore, the DAPA-HF trial evaluated dapagliflozin, another SGLT2 inhibitor, in patients with heart failure with reduced ejection fraction (HFrEF), irrespective of diabetic status. The study demonstrated a significant reduction in the risk of worsening heart failure events and cardiovascular death, highlighting the expanding role of SGLT2 inhibitors as foundational therapy in heart failure management [35].

Future Perspectives

The future of cardiovascular disease (CVD) management is rapidly evolving with the integration of advanced scientific and technological innovations aimed at improving early detection, personalized treatment, and long-term outcomes. One of the most promising approaches is **precision medicine**, which involves tailoring therapeutic strategies based on an individual's genetic makeup, molecular biomarkers, and clinical profile. This approach enables more accurate risk stratification and optimized drug selection, thereby enhancing treatment efficacy while minimizing adverse effects [31].

In parallel, the application of **artificial intelligence (AI)** and machine learning in cardiovascular care is gaining significant momentum. AI-driven algorithms can analyze large datasets from electronic health records, imaging studies, and wearable devices to facilitate early diagnosis, predict disease progression, and identify high-risk individuals. These tools have the potential to assist clinicians in making more informed, data-driven decisions and improving overall patient management [36].

The advancement of **digital health technologies** has further transformed cardiovascular care, particularly through remote patient monitoring and telemedicine. Wearable devices and mobile health applications enable continuous tracking of vital parameters such as heart rate, blood pressure, and physical activity. This real-time monitoring allows for early detection of abnormalities, improved adherence to therapy, and timely clinical interventions, especially in patients with chronic conditions such as heart failure and hypertension [37].

Additionally, there is an increasing emphasis on **preventive cardiology**, which focuses on early identification and modification of risk factors to reduce the incidence of cardiovascular events. Lifestyle interventions, including dietary modifications, regular physical activity, smoking cessation, and stress management, remain fundamental components of prevention strategies. Public health initiatives and community-based programs also play a crucial role in raising awareness and promoting cardiovascular health [15].

CONCLUSION

Cardiovascular diseases continue to be a major global health challenge despite significant advancements in diagnosis and treatment [2]. A comprehensive approach involving risk factor modification, evidence-based pharmacotherapy, and adoption of emerging technologies is essential for effective management [5]. Continued research and innovation are necessary to further reduce the burden of cardiovascular diseases and improve quality of life.

REFERENCES

1. World Health Organization. Cardiovascular diseases (CVDs). Geneva: WHO; 2023.
2. World Health Organization. Global status report on noncommunicable diseases. Geneva: WHO; 2022.
3. Prabhakaran D, Jeemon P, Roy A. Cardiovascular diseases in India. Circulation. 2016;133(16):1605–20.
4. Yusuf S, Hawken S, Ôunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction. Lancet. 2004;364(9438):937–52.
5. Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases. J Am Coll Cardiol. 2020;76(25):2982–3021.
6. GBD 2019 Diseases and Injuries Collaborators. Global burden of disease study 2019. Lancet. 2020;396:1204–22.
7. Gupta R, Mohan I, Narula J. Trends in cardiovascular risk factors in India. J Am Coll Cardiol. 2016;68(25):2745–56.
8. Barquera S, Pedroza-Tobías A, Medina C, et al. Global overview of atherosclerotic cardiovascular disease. Arch Med Res. 2015;46(5):328–38.
9. Joshi P, Islam S, Pais P, et al. Risk factors for early myocardial infarction in South Asians. JAMA. 2007;297(3):286–94.
10. Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868–74.
11. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340(2):115–26.

12. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–95.
13. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of plaque rupture. J Am Coll Cardiol. 2006;47(8):C13–8.
14. Braunwald E. Heart failure pathophysiology. Circulation. 2013;128(20):2215–23.
15. Arnett DK, Blumenthal RS, Albert MA, et al. ACC/AHA guideline on prevention of cardiovascular disease. Circulation. 2019;140(11):e596–646.
16. Grundy SM. Cholesterol and coronary heart disease. JAMA. 1998;279(20):1641–7.
17. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis. JAMA. 2002;287(19):2570–81.
18. Ambrose JA, Barua RS. Smoking and cardiovascular disease. J Am Coll Cardiol. 2004;43(10):1731–7.
19. Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease. Circulation. 2006;113(6):898–918.
20. Mozaffarian D, Wilson PW, Kannel WB. Beyond cholesterol: diet and CVD. Circulation. 2008;117(24):3141–53.
21. Khera AV, Kathiresan S. Genetics of coronary artery disease. Cell. 2017;171(1):44–56.
22. James PA, Oparil S, Carter BL, et al. Hypertension management guidelines. JAMA. 2014;311(5):507–20.
23. Baigent C, Blackwell L, Emberson J, et al. Statins and cardiovascular risk reduction. Lancet. 2010;376(9753):1670–81.
24. Antithrombotic Trialists' Collaboration. Aspirin in prevention of vascular disease. Lancet. 2009;373(9678):1849–60.
25. Ruff CT, Giugliano RP, Braunwald E, et al. Anticoagulants in atrial fibrillation. N Engl J Med. 2014;371(10):972–83.
26. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition in heart failure. N Engl J Med. 2014;371(11):993–1004.
27. Steptoe A, Kivimäki M. Stress and cardiovascular disease. Nat Rev Cardiol. 2012;9(6):360–70.
28. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes (FOURIER trial). N Engl J Med. 2017;376(18):1713–22.
29. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin and cardiovascular outcomes (EMPA-REG). N Engl J Med. 2015;373(22):2117–28.
30. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes. N Engl J Med. 2016;375(4):311–22.
31. Musunuru K. Gene therapy for cardiovascular disease. Nat Rev Cardiol. 2017;14(12):731–47.
32. Madonna R, Van Laake LW, Davidson SM, et al. Stem cell therapy in heart disease. Eur Heart J. 2016;37(23):1789–98.
33. Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in lipid lowering (siRNA therapy). N Engl J Med. 2017;376(15):1430–40.
34. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097–2107.
35. McMurray JJ, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.
36. Johnson KW, Torres Soto J, Glicksberg BS, et al. Artificial intelligence in cardiology. J Am Coll Cardiol. 2018;71(23):2668–2679.
37. Keesara S, Jonas A, Schulman K. Covid-19 and health care's digital revolution (telemedicine). N Engl J Med. 2020;382(23):e82